Ovid Therapeutics Inc.
NASDAQ:OVID
0.3305 (USD) • At close July 2, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.566 | 0.392 | 1.503 | 208.383 | 12.617 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 1.597 | 1.382 | 0 | 0 | 0.255 | 0.142 | 0.08 | 0 | 0.012 | 0 |
| Gross Profit
| 0.566 | -1.205 | 0.121 | 208.383 | 12.617 | -0.255 | -0.142 | -0.08 | -0.057 | -0.012 | 0 |
| Gross Profit Ratio
| 1 | -3.076 | 0.081 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 36.767 | 28.588 | 24.618 | 46.94 | 63.417 | 42.158 | 33.79 | 49.972 | 9.586 | 6.612 | 0.105 |
| General & Administrative Expenses
| 25.683 | 31.085 | 32.433 | 37.233 | 30.631 | 19.252 | 19.142 | 15.035 | 12.95 | 6.578 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 25.683 | 31.085 | 32.433 | 37.233 | 30.631 | 19.252 | 19.142 | 15.035 | 12.95 | 6.578 | 0.342 |
| Other Expenses
| 0.001 | 0 | 1.379 | -2.5 | -0.7 | -4.7 | -1.3 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 62.451 | 59.673 | 57.051 | 84.173 | 94.048 | 61.409 | 52.932 | 65.008 | 22.536 | 13.19 | 0.447 |
| Operating Income
| -61.885 | -59.281 | -55.548 | 124.209 | -81.431 | -61.409 | -52.932 | -65.008 | -22.535 | -13.19 | -0.447 |
| Operating Income Ratio
| -109.337 | -151.345 | -36.964 | 0.596 | -6.454 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 35.452 | 6.943 | 1.379 | -0.046 | 0.395 | 0.948 | 0.952 | 0.202 | 0.121 | 0.03 | 0 |
| Income Before Tax
| -26.433 | -52.339 | -54.169 | 124.163 | -81.036 | -60.461 | -51.98 | -64.806 | -22.414 | -13.16 | -0.447 |
| Income Before Tax Ratio
| -46.701 | -133.622 | -36.047 | 0.596 | -6.423 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -2.761 | 1.329 | -0.307 | -1.203 | 0.952 | -0.08 | -0.001 | 0 | 0 |
| Net Income
| -26.433 | -52.339 | -54.169 | 122.835 | -81.036 | -60.461 | -51.98 | -64.806 | -22.414 | -13.16 | -0.447 |
| Net Income Ratio
| -46.701 | -133.622 | -36.047 | 0.589 | -6.423 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.37 | -0.73 | -0.77 | 1.78 | -1.39 | -1.51 | -2.11 | -3.35 | -1.14 | -0.67 | -0.094 |
| EPS Diluted
| -0.37 | -0.74 | -0.77 | 1.76 | -1.39 | -1.51 | -2.11 | -3.35 | -1.14 | -0.67 | -0.094 |
| EBITDA
| -61.271 | -57.686 | -54.166 | 124.4 | -81.124 | -60.206 | -52.79 | -64.726 | -22.479 | -13.179 | -0.445 |
| EBITDA Ratio
| -108.253 | -147.272 | -36.045 | 0.597 | -6.43 | 0 | 0 | 0 | 0 | 0 | 0 |